Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells
PLOS Biology · 2025
DOI: 10.1371/journal.pbio.3003096 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2025. Verfasst von Ioanna Oikonomidi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research Oncology, Genentech, Inc., South San Francisco, California, United States of America. Hauptthemen laut MEDLINE: Interferon Regulatory Factors, Multiple Myeloma, Protein Serine-Threonine Kinases, Endoribonucleases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) arises through oncogenic transformation of immunoglobulin-secreting plasma cells. MM often co-opts the central endoplasmic reticulum (ER)-stress mitigator, inositol-requiring enzyme 1 (IRE1), to sustain malignant growth. While certain MMs require enzymatic IRE1-dependent activation of the transcription factor XBP1s, others display a nonenzymatic IRE1 dependency that is not yet mechanistically understood. Here we identify interferon regulatory factor 4 (IRF4), which stimulates genes that promote immune-cell proliferation, as a key conduit for IRE1’s nonenzymatic control of cell-cycle progression in MM. IRE1 silencing increased inhibitory S114/S270 phosphorylation on IRF4, disrupting IRF4’s chromatin-binding and transcriptional activity. IRF4 knockdown recapitulated, whereas IRF4 repletion reversed, the anti-proliferative phenotype of IRE1 silencing. Furthermore, phospho-deficient, but not phospho-mimetic, IRF4 mutants rescued proliferation under IRE1 silencing. Functional studies revealed that IRF4 engages the E2F1 and CDC25A genes and promotes CDK2 activation to drive cell-cycle progression. Our results advance mechanistic understanding of IRE1 and IRF4 in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Research Oncology, Genentech, Inc., South San Francisco, California, United States of America.
- Department of Proteomic and Genomic Technologies, Genentech, Inc., South San Francisco, California, United States of America.
ORCID-Profile: Avi Ashkenazi
Zitieren
APA
Oikonomidi, I., Kameswaran, V., Pham, V. C., Zuazo-Gaztelu, I., Gutgesell, L. M., Marsters, S., Daniel, B., Lill, J. R., Modrusan, Z., & Ashkenazi, A. (2025). Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. PLOS Biology. https://doi.org/10.1371/journal.pbio.3003096
Vancouver
Oikonomidi I, Kameswaran V, Pham VC, Zuazo-Gaztelu I, Gutgesell LM, Marsters S, et al. Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. PLOS Biology. 2025. doi:10.1371/journal.pbio.3003096
BibTeX
@article{Oikonomidi2025,
author = {Oikonomidi, Ioanna and Kameswaran, Vasumathi and Pham, Victoria C and Zuazo-Gaztelu, Iratxe and Gutgesell, Lauren M and Marsters, Scot and Daniel, Bence and Lill, Jennie R and Modrusan, Zora and Ashkenazi, Avi},
title = {Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells},
journal = {PLOS Biology},
year = {2025},
doi = {10.1371/journal.pbio.3003096}
}
EUVIMED